(NASDAQ: SLNO) Soleno Therapeutics's forecast annual revenue growth rate of 377.21% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 11,872.19%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 1,482%.
Soleno Therapeutics's revenue in 2026 is $98,675,000.On average, 13 Wall Street analysts forecast SLNO's revenue for 2026 to be $25,291,513,672, with the lowest SLNO revenue forecast at $18,506,863,314, and the highest SLNO revenue forecast at $31,758,737,783.
In 2027, SLNO is forecast to generate $41,066,148,015 in revenue, with the lowest revenue forecast at $33,971,053,712 and the highest revenue forecast at $47,033,868,893.